Atypical Chediak–Higashi Syndrome

Atypical Chediak–Higashi syndrome is the milder, later-onset end of a single disease caused by changes (pathogenic variants) in the LYST gene. In atypical CHS, the usual childhood problems such as frequent severe infections and obvious pale skin or hair can be mild or even absent. Many people are not diagnosed until the teen years or adulthood. The most common problems in atypical CHS are slow, progressive nerve and brain symptoms like tingling or numbness in the feet and hands (peripheral neuropathy), shaky or stiff movements (tremor or parkinsonism), balance trouble (ataxia), and memory or thinking problems. Doctors see the same hallmark sign under the microscope as in classic CHS: giant granules inside white blood cells on a blood smear. Atypical CHS still comes from the same LYST gene problem and belongs on a continuum with the classic childhood form. The risk of a life-threatening immune flare called hemophagocytic lymphohistiocytosis (HLH) is lower than in classic CHS but is not zero. NCBI

Why it happens. The LYST protein helps cells build, move, and empty tiny packets called lysosomes and lysosome-related granules. If LYST does not work well, these packets swell, fuse, or empty poorly. White blood cells then kill germs less effectively, pigment cells bundle pigment abnormally, platelets clump poorly, and nerves may degenerate over time. In atypical CHS, the gene changes usually leave some LYST function. That is why pigment change and infections can be mild while neurologic problems become the main issue later. Medscape+1

 Adults with atypical CHS often have subtle pigment differences, few or no unusual infections, and a mix of nerve and brain problems: neuropathy, tremor, ataxia, and sometimes parkinsonism or cognitive slowing. Studies and case series show that cognitive speed and memory are especially affected in adults with CHS, even when childhood was fairly normal. BioMed Central+1

---

Other names

• Attenuated Chediak–Higashi syndrome (meaning milder). BioMed Central

• Adolescent- or adult-onset CHS (later diagnosis and onset). NCBI

• Mild CHS (a descriptive label within the severity continuum). NCBI

• General names you may see for the condition overall: Chediak–Steinbrinck–Higashi syndrome, oculocutaneous albinism with leukocyte defect, CHS. MedlinePlus

---

Types

These are not official genetic subtypes. They are helpful patterns doctors see along the same disease spectrum:

1. Neurologic-predominant atypical CHS. Later-onset neuropathy, tremor or parkinsonism, ataxia, and gradual cognitive slowing with subtle skin/hair/eye changes and few infections. BioMed Central+1

2. Mixed atypical CHS. Mild pigment change and a past history of some infections, plus adult neuropathy and balance problems. HLH risk is lower than in classic CHS but still possible. NCBI

3. Pigment-minimal atypical CHS. Very subtle pigment findings (sometimes only seen by eye doctors), little bleeding, and late neurologic symptoms; diagnosis often delayed unless a blood smear is reviewed. NCBI

These patterns sit on a continuum from severe childhood-onset to milder adult-onset disease. The unifying sign is giant granules in white blood cells. NCBI

---

Causes and contributors

Important note: Atypical CHS is caused by biallelic pathogenic variants in the LYST gene. The items below group the root cause and factors that make the course milder or trigger complications. NCBI+1

1. Biallelic LYST variants (autosomal recessive inheritance). Core cause of all CHS. MedlinePlus

2. Hypomorphic (partial-function) missense variants that leave some LYST activity, often linked with milder, later-onset disease. NCBI

3. Small in-frame deletions (for example, the adult sibship with a two-amino-acid deletion) associated with attenuated, adult neurodegenerative presentation. PubMed

4. Splice-site or exon-skipping variants that reduce, but do not abolish, normal protein and can soften non-neurologic features. NCBI

5. Compound heterozygosity (two different LYST variants) with at least one milder allele. Medscape

6. Maternal uniparental isodisomy of chromosome 1 leading to LYST homozygosity in rare cases. NCBI

7. Genotype–phenotype correlations (truncations often severe/early; many missense changes → milder/late). This is a trend, not absolute. Medscape

8. Residual lysosome trafficking function in immune cells (enough to avoid constant severe infections) but not in neurons (later degeneration). NCBI

9. Abnormal pigment granule handling (giant melanosomes) that may be subtle clinically yet visible on microscopy. NCBI

10. Platelet dense-granule defects that cause mild bleeding and bruising, which may be unnoticed for years. NCBI

11. Age-related neuronal vulnerability—adult neurodegeneration despite earlier stable health. BioMed Central

12. Inflammatory “accelerated phase” (HLH) triggers like viral infections (especially EBV) that can still occur, though less often than in classic CHS. Medscape

13. Natural killer (NK) cell dysfunction and impaired neutrophil killing that shape infection risk and HLH susceptibility. NCBI

14. Periodontal disease as a clue to subtle immune dysfunction in milder phenotypes. NCBI

15. Neutropenia (intermittent or chronic)—when present, it increases infections and may unmask the diagnosis. BioMed Central

16. Defective plasma-membrane repair and exocytosis in “beige/CHS” cells, impairing cellular resilience. BioMed Central

17. Oxidative membrane damage in model systems, proposed as a driver of neurodegeneration. BioMed Central

18. Cerebellar and cortical atrophy developing over time, correlating with adult motor and cognitive slowing. BioMed Central

19. Underrecognition/delayed diagnosis because pigment and infection signs are mild; without smear review, giant granules can be missed. BioMed Central+1

20. Family consanguinity increasing the chance of inheriting two LYST variants in some populations/families. Medscape

---

Symptoms

1. Subtle skin and hair lightening (sometimes only a silvery sheen). Often mild in atypical CHS. NCBI

2. Light sensitivity of the eyes and other mild vision issues (sometimes only on exam). NCBI

3. Reduced or patchy eye pigment on specialist eye exam. NCBI

4. Easy bruising or mild nose/gum bleeding due to platelet granule problems. NCBI

5. Occasional or fewer infections than classic CHS; some adults report only typical infections. NCBI

6. Periodontal disease or gum problems out of proportion to routine care. NCBI

7. Numbness, tingling, or burning pain in feet/hands (peripheral neuropathy). NCBI

8. Unsteady walking and balance trouble (ataxia). NCBI

9. Tremor or stiffness that may resemble Parkinson’s disease in young adults. NCBI+1

10. Weakness and slower movements, especially fine motor tasks. BioMed Central

11. Cognitive slowing—especially slower thinking speed and memory problems in adulthood. BioMed Central

12. Learning difficulties reported earlier in life in some adults later diagnosed with CHS. BioMed Central

13. Fatigue related to infections, anemia, or neurologic effort. (General feature consistent with the disorder’s multisystem burden.) NCBI

14. Fever, enlarged spleen or liver, or cytopenias if an HLH episode occurs. NCBI+1

15. Headache or seizures (less common, part of neurologic involvement). MedlinePlus

---

Diagnostic tests

A) Physical examination

1. Full skin and hair exam. Look for subtle lightening or a silvery sheen; check for easy bruises. This supports the diagnosis but can be mild in atypical cases. NCBI

2. Eye exam with penlight and basic vision check. Photophobia, nystagmus, or reduced acuity may be subtle clues; a full ophthalmology visit is still needed. NCBI

3. Mouth and gum exam. Periodontal disease and mucosal bleeding are common hints of platelet and immune issues. NCBI

4. Neurologic exam. Check vibration, pinprick, reflexes, gait, tandem walk, and coordination for neuropathy or ataxia. NCBI

5. Spleen/liver palpation and lymph node check. Helps screen for HLH (accelerated phase) in any patient with fevers or cytopenias. NCBI

B) Manual / bedside tests

6. Visual acuity and contrast sensitivity charts. Quantify subtle visual loss seen in CHS-related albinism. NCBI

7. Slit-lamp and iris transillumination (by ophthalmology). Finds reduced iris pigment even when eye color looks normal. NCBI

8. Hair-shaft light microscopy. Can show clumped melanin in the hair shaft in CHS and supports pigment handling defects. NCBI

9. Bedside gait and balance tests (Romberg, heel-to-toe). Simple screens for ataxia and proprioceptive loss. NCBI

10. Bedside cognitive screening (e.g., attention and memory tasks). Adults with CHS often show slowed processing and memory difficulties. BioMed Central

C) Laboratory & pathological tests

11. Complete blood count (CBC) with peripheral smear review. The key diagnostic clue is giant granules inside neutrophils and other leukocytes; they can be missed unless someone actually looks at the smear. NCBI

12. Bone marrow smear/aspirate (when needed). Confirms giant azurophilic granules and helps assess cytopenias or HLH. NCBI

13. LYST gene testing (molecular testing). Confirms two pathogenic variants; helpful for family counseling. NCBI

14. Neutrophil function tests (oxidative burst/chemotaxis) and NK-cell activity. These show immune cell defects that explain infections and HLH risk. NCBI

15. Platelet studies (dense-granule assessment; platelet aggregation). Explain easy bruising and mild bleeding. NCBI

16. HLH screening labs during fevers: ferritin, triglycerides, fibrinogen, soluble IL-2 receptor, plus blood counts. These support HLH criteria in CHS. NCBI

17. Immunoglobulin levels and vaccine responses. Evaluate baseline immune function and guide preventive care. (Supported within broader CHS immune workups.) Medscape

18. Cultures/PCR for triggers (e.g., EBV) in suspected HLH or severe illness. EBV can precipitate HLH in CHS. Medscape

D) Electrodiagnostic tests

19. Nerve conduction studies and EMG. Define the pattern and severity of peripheral neuropathy (axonal or demyelinating) common in adult CHS. Medscape

20. EEG (if seizures) and evoked potentials (as needed). Assess central nervous system involvement beyond standard imaging. (Part of neurologic evaluation frameworks in CHS.) NCBI

E) Imaging tests

21. Brain MRI. Often shows cerebellar and cerebral atrophy or white-matter changes that match motor slowing and memory issues in adult CHS. BioMed Central+1

22. Optical coherence tomography (OCT). Measures retinal nerve fiber thickness and pigment-related changes; useful baseline in CHS. NCBI

23. Chest imaging (X-ray/CT) during infections. Looks for pneumonia or other complications when immune defense is impaired. (Standard infection workup referenced within CHS care.) Medscape

24. Abdominal ultrasound. Checks spleen and liver size and helps evaluate HLH or longstanding disease burden. BioMed Central

Non-pharmacological treatments (therapies & others)

(Each item: ~150 words with purpose & mechanism; all are supportive and should be personalized by the care team.)

1. Personalized infection-prevention plan – Work with an immunologist to make a written plan for fever, cuts, dental problems, or cough. The purpose is to find and treat infections early. The mechanism is simple: set clear thresholds (e.g., fever ≥38.0 °C) for urgent cultures and antibiotics, extend treatment courses beyond usual durations, and consider prophylaxis if infections repeat. This plan reduces delays and prevents severe illness. Medscape+1

2. Vaccination with inactivated vaccines – Use routine inactivated vaccines (e.g., influenza, pneumococcal) per schedule; live vaccines are generally avoided if immune function is impaired. The purpose is to lower infection risk. Mechanism: trigger protective antibody and T-cell responses without the risks of live vaccine replication in immune-compromised hosts. Decisions should be individualized. NCBI

3. Antimicrobial prophylaxis (select cases) – In people with frequent or severe infections, clinicians may consider targeted antibiotic prophylaxis; some centers also consider Pneumocystis or NTM coverage in special scenarios. Purpose: reduce infection frequency and severity. Mechanism: constant low-dose antimicrobials suppress colonizing pathogens in high-risk periods. Evidence in primary immunodeficiencies is limited and practice varies; this should be specialist-guided. Lippincott Journals

4. Dental and gum care program – CHS can cause periodontitis and mouth infections. Purpose: prevent tooth loss and bacteremia. Mechanism: frequent professional cleanings, home chlorhexidine swishes if prescribed, flossing, soft-bristle brushing, and early treatment of gingival swelling or abscess. This lowers bacterial load and prevents systemic spread. Medscape

5. Skin protection & wound hygiene – Pale skin burns easily. Purpose: prevent skin infection and scarring. Mechanism: daily emollients for barrier support, broad-spectrum sunscreen, protective clothing, careful wound cleaning, and early evaluation of boils or cellulitis. NCBI

6. Low-vision support – Many have nystagmus, photophobia, or reduced acuity. Purpose: improve function and safety. Mechanism: corrective lenses, tint filters, high-contrast materials, magnifiers, and classroom/workplace accommodations. NCBI

7. Neurologic rehabilitation – With neuropathy and ataxia, people lose balance and strength. Purpose: maintain mobility and independence. Mechanism: physical therapy for gait and balance, occupational therapy for activities of daily living, speech therapy if dysarthria or swallowing issues appear. BioMed Central

8. Fall-prevention program – Purpose: cut risk of fractures and head injury. Mechanism: home safety check, assistive devices, strength/balance exercises, and medication review for sedating drugs that worsen falls. BioMed Central

9. Parkinsonism strategies – Some adults develop parkinsonian features. Purpose: ease slowness, rigidity, and gait freezing. Mechanism: cueing, task breakdown, rhythmic gait training, and energy conservation. Drug options are individualized (see below). Movement Disorders

10. Cognitive support & accommodations – Purpose: support learning and work success. Mechanism: neuropsychological testing, memory aids, extra time for tasks, reduced sensory overload, and job or school adjustments. BioMed Central

11. Nutrition & infection-recovery support – Purpose: keep weight and immunity stable during/after infections. Mechanism: adequate protein, hydration, and micronutrients guided by a dietitian; watch for drug–nutrient issues during long antibiotic courses. Medscape

12. Sunlight/photophobia management – Purpose: reduce eye strain and skin damage. Mechanism: brimmed hats, UV-blocking sunglasses, indoor light control, and scheduled breaks. NCBI

13. Psychological support – Purpose: reduce stress, anxiety, and mood effects of a chronic rare disease. Mechanism: counseling, peer support, and coping skills; stress reduction can improve sleep and infection vigilance. BioMed Central

14. Home fever protocol – Purpose: avoid delays in care. Mechanism: keep a thermometer, antiseptics, clinician instructions, and emergency contacts; seek urgent care at set fever thresholds. Medscape

15. Peri-dental and peri-procedural antibiotic plans – Purpose: lower risk of bacteremia during dental work or minor surgery when indicated. Mechanism: pre-procedure antibiotics per specialist guidance. Medscape

16. Vision-safe reading & screen habits – Purpose: reduce eye fatigue. Mechanism: high-contrast fonts, larger text, and scheduled breaks; photo-filters as tolerated. NCBI

17. Occupational safety adjustments – Purpose: reduce exposure to infection and injury. Mechanism: avoid high-germ or high-trauma jobs; ensure protective gear and flexible schedules. BioMed Central

18. Care coordination – Purpose: align hematology/immunology, neurology, ophthalmology, dentistry, rehab, and transplant teams. Mechanism: shared care plans and regular case reviews. NCBI

19. Pre-transplant optimization (if HSCT planned) – Purpose: improve transplant readiness. Mechanism: treat active infections, update inactivated vaccines, dental clearance, nutrition, and rehab baseline testing. NCBI

20. Genetic counseling for family – Purpose: explain inheritance, carrier testing, and options for future pregnancies. Mechanism: review autosomal recessive risks and discuss testing pathways. NCBI

---

Drug treatments

(High-yield options used for CHS itself, its complications, or its HLH “accelerated phase.” Each entry ~150 words includes class, typical dosing guidance highlights, purpose, mechanism, key side effects. Doses are general; individualize with your specialist.)

1. Dexamethasone (HLH induction) – Class: glucocorticoid. Dose/time: HLH-94 uses high-dose dexamethasone tapered over 8 weeks; exact body-surface-area dosing is protocolized. Purpose: rapidly suppress hyper-inflammation. Mechanism: broad cytokine inhibition (e.g., IL-1, IL-6, TNF) and lymphocyte apoptosis. Side effects: hyperglycemia, infection risk, mood changes, myopathy, gastric irritation. Use gastro-protection and infection monitoring. ASH Publications+1

2. Etoposide (HLH induction) – Class: topoisomerase II inhibitor. Dose/time: HLH-94 uses 150 mg/m² IV at protocol intervals. Purpose: delete activated T-cells and macrophages driving HLH. Mechanism: DNA strand breaks in rapidly dividing immune cells. Side effects: myelosuppression, mucositis, hepatic toxicity, infection risk; requires close counts monitoring. ASH Publications

3. Cyclosporine A (HLH protocols/continuation) – Class: calcineurin inhibitor. Dose/time: per HLH-94/2004 continuation phases. Purpose: maintain control of immune activation. Mechanism: blocks IL-2 transcription and T-cell activation. Side effects: hypertension, nephrotoxicity, tremor, gingival hyperplasia; monitor drug levels. ASH Publications

4. Emapalumab-lzsg (Gamifant®) – Class: anti-interferon-γ monoclonal antibody. Dose/time: weight-based IV; used for refractory, recurrent, or progressive primary HLH, and (in the U.S.) also for HLH/MAS in Still’s disease after steroids. Purpose: neutralize IFN-γ to stop the HLH cytokine storm. Mechanism: binds IFN-γ, reducing macrophage over-activation. Side effects: infection risk (esp. TB), infusion reactions; screen for latent infections. FDA Access Data+2U.S. Food and Drug Administration+2

5. Broad-spectrum IV antibiotics (febrile neutropenia or severe infection) – Class: antibacterial (e.g., antipseudomonal β-lactam). Dose/time: per sepsis/febrile-neutropenia guidelines; courses may be 2–3× longer than usual in CHS. Purpose: promptly treat likely pathogens. Mechanism: bactericidal activity matched to local antibiogram. Side effects: C. difficile risk, drug reactions; adjust for kidneys. Medscape

6. Oral antibiotic prophylaxis (selected patients) – Class: antibacterial. Dose/time: low-dose daily or thrice-weekly regimens customized by history. Purpose: prevent recurrent bacterial infections. Mechanism: suppress colonizing bacteria. Side effects: resistance, GI upset; re-assess need regularly. Evidence in primary immunodeficiency is limited. Lippincott Journals

7. Acyclovir or valacyclovir (viral prophylaxis/therapy) – Class: antiviral. Dose/time: per standard HSV/VZV protocols or prophylaxis plans in high-risk periods. Purpose: prevent or treat herpesvirus infections. Mechanism: viral DNA polymerase inhibition after phosphorylation. Side effects: renal toxicity (rare), headache; hydrate well. MedlinePlus

8. Trimethoprim–sulfamethoxazole (PJP prophylaxis when indicated) – Class: antibacterial/antiprotozoal. Dose/time: intermittent low-dose regimens (e.g., 2–3× weekly) when PJP risk is high. Purpose: prevent Pneumocystis pneumonia. Mechanism: folate pathway blockade in microbes. Side effects: sulfa allergy, cytopenias, hyper-K⁺; monitor labs. Lippincott Journals

9. G-CSF (filgrastim) for neutropenia – Class: hematopoietic growth factor. Dose/time: individualized (e.g., daily or intermittent injections). Purpose: increase neutrophils, reduce infection days. Mechanism: stimulates myeloid progenitors to mature and release neutrophils. Side effects: bone pain, leukocytosis; high cumulative doses may have long-term risks in congenital neutropenia—use the lowest effective dose. PMC+2New England Journal of Medicine+2

10. Topical/short systemic antifungals (as needed) – Class: azoles/allylamines. Dose/time: per diagnosis (e.g., candidiasis, tinea). Purpose: treat fungal skin/mucosal infections promptly. Mechanism: block ergosterol synthesis. Side effects: hepatic interactions (oral azoles); monitor. Medscape

11. IVIG (selected scenarios) – Class: pooled immunoglobulin. Dose/time: intermittent infusions when there is significant hypogammaglobulinemia or recurrent infections not controlled otherwise. Purpose: provide passive antibodies. Mechanism: supplement humoral immunity. Side effects: headaches, aseptic meningitis (rare); premedicate if needed. NCBI

12. Interferon-gamma (IFN-γ) replacement (older reports, selective use) – Class: cytokine therapy. Dose/time: subcutaneous dosing in some immunodeficiencies; limited data in CHS. Purpose: enhance macrophage microbicidal function. Mechanism: boosts phagocyte killing pathways. Side effects: flu-like symptoms, cytopenias; use only under specialist guidance. Merck Manuals

13. Levodopa/carbidopa (parkinsonism in adults) – Class: dopaminergic. Dose/time: titrate to effect. Purpose: improve rigidity/bradykinesia in CHS-related parkinsonism. Mechanism: dopamine replacement. Side effects: nausea, dyskinesia, orthostasis; monitor response. Movement Disorders

14. Amantadine (gait/freezing, fatigue) – Class: dopaminergic/antiviral. Dose/time: per standard PD dosing. Purpose: reduce fatigue and improve gait in parkinsonian features. Mechanism: enhances dopamine release and reduces reuptake. Side effects: insomnia, edema; adjust for kidneys. Movement Disorders

15. Baclofen or tizanidine (spasticity) – Class: antispasticity agents. Dose/time: start low, go slow. Purpose: ease muscle tightness from central nervous system involvement. Mechanism: GABA-B agonism (baclofen) or α2-agonism (tizanidine). Side effects: sedation, weakness. BioMed Central

16. Gabapentin/pregabalin (neuropathic pain) – Class: calcium-channel ligands. Dose/time: titrate to pain and function. Purpose: reduce neuropathic tingling/burning. Mechanism: reduces excitatory neurotransmitter release. Side effects: dizziness, somnolence. PMC

17. SSRI/SNRI (mood/anxiety related to chronic illness) – Class: antidepressants. Dose/time: standard psychiatric dosing. Purpose: support mental health during long treatment journeys. Mechanism: serotonin ± norepinephrine reuptake blockade. Side effects: GI upset, sleep changes. BioMed Central

18. Prokinetics/laxatives PRN – Class: GI motility agents. Dose/time: short courses as needed. Purpose: counter constipation or GI slow-down from opioids or neurologic disease. Mechanism: enhance GI transit or soften stool. Side effects: cramps; use judiciously. BioMed Central

19. Antiemetics during chemotherapy (HLH therapy/HSCT) – Class: 5-HT3 antagonists, etc. Dose/time: per regimen. Purpose: reduce nausea, keep nutrition adequate. Mechanism: block emetogenic pathways. Side effects: constipation, QT effects (agent-specific). ASH Publications

20. Topical ocular lubricants & anti-inflammatories – Class: eye care agents. Dose/time: per ophthalmology. Purpose: reduce irritation and photophobia from ocular surface disease and albinism-related strain. Mechanism: tear film support and inflammation control. Side effects: minimal; follow eye doctor’s plan. NCBI

---

Dietary molecular supplements

(Supportive only; none cure CHS. Discuss with your clinician—watch for interactions with antibiotics, chemo, or calcineurin inhibitors.)

1. Vitamin D – Adequate vitamin D supports respiratory infection risk reduction in many populations. Dose: per lab levels (often 800–2000 IU/day; individualized). Function/mechanism: modulates innate and adaptive immunity, improving antimicrobial peptides and tempering excess inflammation. Evidence is general, not CHS-specific. Lippincott Journals

2. Vitamin C – Dose: 200–500 mg/day typical. Function: antioxidant support during infections and wound healing. Mechanism: scavenges reactive oxygen species and supports collagen formation; may help oral health with good dental care. Evidence in CHS is extrapolated. Medscape

3. Zinc – Dose: short-term 10–20 mg elemental/day if deficient. Function: supports neutrophil and NK-cell function. Mechanism: cofactor for many immune enzymes. Avoid chronic high doses (copper deficiency risk). NCBI

4. Omega-3 fatty acids (fish oil) – Dose: 1–2 g/day EPA+DHA if tolerated. Function: anti-inflammatory support for joints/nerve discomfort. Mechanism: competing with arachidonic acid to lessen pro-inflammatory eicosanoids. Watch bleeding risk if platelets are low. NCBI

5. Probiotics (selected strains) – Dose: per product; use cautiously in immunocompromise. Function: support gut barrier during antibiotics. Mechanism: compete with pathogens and modulate mucosal immunity; avoid if central lines or severe neutropenia without doctor approval. Lippincott Journals

6. Folate/B-complex – Dose: per labs/diet. Function: support hematopoiesis under chronic inflammation or drug therapy. Mechanism: coenzymes for DNA synthesis in marrow cells. NCBI

7. Iron (only if iron-deficient) – Dose: per ferritin/TSAT. Function: treat iron-deficiency anemia that can worsen fatigue. Mechanism: restores hemoglobin synthesis; avoid if infections uncontrolled. NCBI

8. Calcium + vitamin D (bone health) – Dose: per age/sex and labs. Function: protect bone during steroids and reduced mobility. Mechanism: supports bone remodeling; pair with weight-bearing exercise as able. ASH Publications

9. Coenzyme Q10 – Dose: 100–200 mg/day. Function: energy support in chronic illness; evidence modest. Mechanism: mitochondrial electron transport support; may help fatigue in some patients. BioMed Central

10. Turmeric/curcumin (food-based) – Dose: culinary amounts; supplements only with clinician approval. Function: general anti-inflammatory effects. Mechanism: NF-κB and cytokine modulation. Watch for drug interactions (e.g., cyclosporine). ASH Publications

---

Immunity-booster / regenerative / stem-cell–oriented drugs

(Supportive or disease-modifying; 100-word summaries)

1. Hematopoietic stem-cell transplantation (HSCT) – Dose: procedure with conditioning chemo. Function: replaces defective immune system and corrects blood/immune defects. Mechanism: donor stem cells engraft and make normal neutrophils/NK cells. Neurologic decline may continue, so rehab remains vital. NCBI+1

2. G-CSF (filgrastim) – Dose: individualized SC injections. Function: raises ANC to cut infection risk. Mechanism: stimulates marrow myeloid line. Use lowest effective dose; long-term high doses in congenital neutropenia carry theoretical leukemogenesis concerns—specialist follow-up needed. PMC+1

3. IVIG – Dose: intermittent IV infusions. Function: passive antibody support in selected patients with low Ig or recurrent infections. Mechanism: supplement humoral immunity and modulate inflammation. NCBI

4. Emapalumab-lzsg – Dose: weight-based IV. Function: controls refractory HLH to allow recovery or bridge to HSCT. Mechanism: neutralizes IFN-γ driving macrophage over-activation. FDA Access Data

5. Alemtuzumab / salvage immunochemotherapy (selected HLH) – Dose: per specialist protocols. Function: rescue therapy in refractory HLH. Mechanism: depletes activated lymphocytes. Risks: profound immunosuppression; center-level decision. ASH Publications

6. Future gene therapy (investigational) – Dose: not yet standard. Function: aims to fix LYST defect directly. Mechanism: gene addition/editing in stem cells; preclinical stage. Follow trials via specialists. BioMed Central

---

Surgeries/procedures

1) Hematopoietic stem-cell transplantation (HSCT): replaces the faulty immune system to correct the hematologic and immunologic part of CHS; done to reduce life-threatening infections and HLH episodes. NCBI

2) Central venous catheter placement (when needed): done to safely deliver chemo, IV antibiotics, IVIG, or transplant conditioning when long-term venous access is required. ASH Publications

3) Dental surgeries (extractions, drainage of abscesses): performed for periodontal disease or deep infections to stop seeding of bacteria to the blood. Medscape

4) Ophthalmic procedures (selected): lens/strabismus or low-vision interventions to improve visual function in people with significant ocular involvement. NCBI

5) Surgical debridement/drainage of skin–soft tissue infections: used when abscesses or necrotic tissue are present to reduce bacterial load and speed healing, alongside antibiotics. MedlinePlus

---

Prevention tips

1. Have a fever plan and act fast—know when to seek urgent care. Medscape

2. Keep vaccines up to date with inactivated vaccines. NCBI

3. Daily mouth care and regular dentist visits. Medscape

4. Protect skin and eyes from sun and injury. NCBI

5. Practice hand hygiene and avoid close contact during outbreaks. NCBI

6. Treat infections longer than usual when your doctor advises. Medscape

7. Consider prophylaxis if infections repeat—specialist decision. Lippincott Journals

8. Keep nutrition and sleep steady to support recovery. Medscape

9. Prevent falls with home safety and exercise. BioMed Central

10. Coordinate care across specialists; keep a shared plan. NCBI

---

When to see a doctor (or go to the ER)

Seek urgent care now for fever ≥38.0 °C, shaking chills, shortness of breath, chest pain, severe headache, confusion, stiff neck, fast-spreading skin redness, or any wound that is rapidly worsening. This is because people with CHS can get severe infections or HLH, which needs rapid treatment. Medscape+1

Call your team soon (within 24–48 h) if you have new numbness, weakness, balance problems, worsening tooth/gum pain, repeated mouth ulcers, new vision changes, or easy bruising/bleeding. Early checks prevent complications and guide antibiotics or other therapies. BioMed Central

---

What to eat and what to avoid

Eat: regular meals with adequate protein, fruits/vegetables, whole grains, and fluids. During illness, choose soft, high-protein foods and oral rehydration if needed. This supports immune recovery and helps tolerate long antibiotic courses. Medscape

Avoid or limit: undercooked meats/eggs, unpasteurized dairy, raw sprouts, and buffet foods that sit at room temperature—these carry higher infection risk when immunity is weak. If platelets are very low, be cautious with alcohol and high-dose omega-3; discuss supplements like turmeric or zinc with your clinician to avoid drug interactions. Medscape+1

---

Frequently asked questions

1) Is atypical CHS the same as classic CHS?
No. Atypical CHS usually starts later, with milder infections but more neurologic issues in adulthood. Both are due to LYST variants. NCBI

2) Can HSCT cure atypical CHS?
HSCT can fix the immune and blood problems, but it may not stop later neurologic decline, so rehab stays important. NCBI

3) What is HLH and why is it dangerous?
HLH is an extreme immune over-activation crisis. It causes high fever and organ injury. Doctors treat it urgently with dexamethasone + etoposide ± cyclosporine or emapalumab in selected cases. ASH Publications+2ASH Publications+2

4) Do all people with atypical CHS get HLH?
Risk is lower than in classic CHS but still present; rapid evaluation for fever is key. NCBI

5) What infections are most common?
Recurrent bacterial skin, respiratory, and dental infections are typical; fungal and viral infections also occur. NCBI

6) Are live vaccines allowed?
Most experts use inactivated vaccines and avoid live vaccines when immune function is impaired; decisions are individualized. NCBI

7) Can G-CSF help low neutrophils?
Yes, case reports show ANC rise and fewer infections with G-CSF; use the lowest effective dose and follow with specialists. PMC+1

8) Does long-term G-CSF have risks?
In congenital neutropenia broadly, high cumulative dosing may be linked to leukemogenesis; this needs careful specialist monitoring. ScienceDirect

9) Can adults with parkinsonism improve?
Some improve with dopaminergic therapy and rehab, though responses vary. Movement Disorders

10) What about interferon-gamma as a medicine?
Older references suggest possible immune support in CHS, but evidence is limited; it must be specialist-guided. Merck Manuals

11) Does emapalumab replace chemotherapy for HLH?
It is approved for refractory/recurrent primary HLH and can be a bridge to HSCT; clinicians choose based on the case. FDA Access Data+1

12) Are there special dental steps?
Yes. Frequent cleanings, chlorhexidine if prescribed, and early treatment of gum disease. This lowers bacteremia risk. Medscape

13) How long are antibiotic courses?
Often longer than usual—sometimes 2–3×—to fully clear infections in CHS. Medscape

14) Is gene therapy available?
Not yet. It remains investigational; ask your center about trials. BioMed Central

15) Where can I read a clinician-level overview?
See GeneReviews® for CHS, Orphanet for disease summaries, and Blood guidelines for HLH management. NCBI+2Orpha+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 28, 2025.

PDF Documents For This Disease Condition References